Please login to the form below

opioids

This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.

NCI head Sharpless named as interim FDA chief

There will be no let-up in the agency’s focus, from ongoing efforts on drug approvals and combating the opioid crisis to modernising food safety and addressing the rapid rise

Latest news

Lilly, Pfizer say NGF drug works in back pain too

The market for drugs that deliver effective pain relief without the risk of side effects and addiction linked to opioid analgesics could be massive, and that is driving the development of ... In contrast to opioids, which alter pain perception by
FDA panel backs J&J’s new-class antidepressant

One of the big questions for the FDA panel was whether J&J would be able to mitigate concerns that the drug activates opioid receptors in the brain and so could
Ashfield partners with MIMS, WA Health wins new account and Lighthouse relocates

UK launch of Camurus’ opioid replacement therapy treatment.
Nektar confirms BMS deal for NKTR-214 is on track

Almost forgotten among the interest in Nektar’s immuno-oncology pipeline – which also includes three other candidates in clinical trials – is NKTR-181, a first-in-class, abuse-deterrent opioid analgesic ... The drug promises to deliver pain relief
Brexit contributes to surge in generic drug prices

He says some medicines would be “particularly vulnerable" - highlighting a current shortage of pain and opioid addiction treatment Buprenorphine and antipsychotic Risperidone, arising in particular because there are no simple alternatives

More from news
Approximately 15 fully matching, plus 127 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

About 2.5m people have been diagnosed with opioid dependence in the US, and almost one million are receiving treatment. ... New to the opioid dependence treatment market this year is CAM2038, marketed by Camurus, a company headquartered in Lund, Sweden.
Pharma deals continue to slide

These companies have been running out of cash and have had to do deals to stay alive. Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase
Grünenthal's relentless pursuit of relief

It has the potential to reduce pain without typical opioid therapy side effects and is in development for topical application in hypersensitivity disorders such as Bladder Pain Syndrome or Chronic Stump
How digital content helps HCPs curb opioid abuse through better prescribing decisions

In fact, a poll of physicians within our digital community found that 64% believe that doctors have a responsibility to help curb opioid abuse. ... And by delivering information concisely and in an engaging format, this approach is having a measurable
Deal Watch March 2016

$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.

More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest appointments

Egalet appoints Stan Musial as CFO

s pipeline of abuse-deterrent opioids are nearing phase III.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report

The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018. ... The two-day event succeeded in delivering what IOTOD is well known for: expert
IOTOD: Improving Opioid Dependence Outcomes

IOTOD’s future. The IOTOD educational initiative perpetually aims to provide the most up-to-date information in the field of opioid addiction. ... in opioid addiction and gain valuable insight on some of the most controversial topics in the field.
"Legal highs" ruling leaves illegal labs laughing

So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. . ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse. .
Research Partnership has published a new Living with Chronic Pain market report for 2016

At least 60% of the patients surveyed are currently prescribed long acting opioids (LAOs).
How digital content is helping physicians curb the opioid abuse epidemic

using their state’s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... topic. And there’s plenty of evidence that this approach works—having a measurable and almost immediate impact on how physicians

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Home based, Senior Medical Writer, Medical Communications: Excellent package

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Director – Healthcare Advertising – London: Salary TBC

Home-based Senior Medical Writer – Med Ed: Salary TBC

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Programme/ Account Director - Healthcare PR - London: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Marketing Agency: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Creative/ Medical Writer: Circa £35, 000 With Benefits

Digital Account Director: Salary TBC

Scientific Director – Medical Communications: Salary TBC

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Freelance AM/ AD Healthcare Advertising: £350-400 depending on experience

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

Home-based Medical Writer – Medical Education: Salary TBC

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Senior Account Manager, Medical Communications, London: Excellent package

Health Consultant - Brand Comms: Competitive Salary

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....